Skip to main content

Market Overview

Why InflaRx Shares Are Ripping Higher Thursday

Share:
Why InflaRx Shares Are Ripping Higher Thursday

InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why. 

What Happened: German biopharma InflaRx, which focuses on developing therapies for autoimmune and inflammatory diseases, announced positive data Wednesday from the third cohort of patients in the Phase 2a study of vilobelimab in Pyoderma Gangraenosum.

PG is a rare and debilitating neutrophil-driven, autoinflammatory skin disease, characterized by an acute, destructive ulcerating process of the skin, primarily occurring on the legs but also other regions of the body. It can lead to chronic, painful and difficult-to-treat wounds with long healing times.

In the third dosing cohort at the highest dose level of 2,400 mg biweekly, six of the seven patients achieved clinical remission with a PGA score of less than or equal to 1, which reflects a closure of the target ulcer. Overall, vilobelimab was also well tolerated.

Related Link: The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs

Sell-Side Review Of Data Reason Behind Upside? The stock reaction was muted following the Wednesday morning data release.

After opening Wednesday's session up 1.8% at $2.91, the stock traded in a $2.78-$3 range before ending unchanged at $2.86.

Following the release of the data, SVB Leerink analyst Joseph Schwartz reiterated an Outperform rating on the shares.

Terming the data as compelling, HC Wainwright analyst Edward White reiterated a Buy rating and increased the price target from $10 to $11.

Raymond James analyst Steven Seedhouse upgraded the stock from Outperform to a Strong Buy and also upped the price target from $10 to $14, suggesting roughly 400% upside from current levels.

IFRX Price Action: In premarket trading Thursday, InflaRx shares were jumping 31.79% to $3.77

Related Link: The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug

Latest Ratings for IFRX

DateFirmActionFromTo
Nov 2021Raymond JamesMaintainsStrong Buy
Oct 2021Raymond JamesUpgradesOutperformStrong Buy
Aug 2021Raymond JamesMaintainsOutperform

View More Analyst Ratings for IFRX

View the Latest Analyst Ratings

 

Related Articles (IFRX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Penny Stocks Upgrades Price Target Reiteration Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com